Provided by Tiger Trade Technology Pte. Ltd.

Health in Tech

1.00
-0.0200-1.96%
Post-market: 0.9900-0.0100-1.00%19:32 EDT
Volume:66.80K
Turnover:67.75K
Market Cap:65.53M
PE:-15.31
High:1.03
Open:0.9906
Low:0.9600
Close:1.02
52wk High:4.02
52wk Low:0.8501
Shares:65.53M
Float Shares:20.19M
Volume Ratio:0.43
T/O Rate:0.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0653
EPS(LYR):0.0200
ROE:-21.91%
ROA:-12.72%
PB:3.35
PE(LYR):50.00

Loading ...

Health In Tech Files $300 Million Mixed Shelf Registration

MT Newswires Live
·
Jun 12

Health In Tech files $300M mixed securities shelf

TIPRANKS
·
Jun 12

Health in Tech - May Offer up to $300 Mln in Common Stock, Preferred Stock, Warrants, Debt, Rights, and Units - SEC Filing

THOMSON REUTERS
·
Jun 12

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

GlobeNewswire
·
Jun 03

Yantian International, Chengdu Land Port Company, and HIT Sign Cooperation Agreement

Deep News
·
May 29

One-Year Milestone for Chengdu-Shenzhen-Hong Kong Scheduled Rail Service: Fostering Trilateral Synergy and Bolstering the Real Economy

Deep News
·
May 29

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

GlobeNewswire
·
May 20

Health In Tech Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Health In Tech reports Q1 EPS (3c), consensus (2c)

TIPRANKS
·
May 14

Health In Tech backs FY26 revenue view $45M-$50M, consensus $46.36M

TIPRANKS
·
May 14

Health In Tech Q1 EPS $(0.03), Inline, Sales $4.509M Miss $7.349M Estimate

Benzinga Earnings
·
May 14

Health In Tech Q1 FY26 turns to net loss of $1.6 million; revenue rises 9.4% to $8.8 million

Reuters
·
May 14

Press Release: Health In Tech Reports First Quarter 2026 Financial Results

Dow Jones
·
May 14

Health In Tech Inc expected to post a loss of 3 cents a share - Earnings Preview

Reuters
·
May 12

Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Dow Jones
·
May 07

Health in Tech AI, marketing chief Dustin Plantholt departs amid business transition

Reuters
·
May 02

Health In Tech to report first-quarter results after market close May 13

Reuters
·
May 01

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

GlobeNewswire
·
Apr 30

Health In Tech files to sell 5.6M shares of Class A common stock for holders

TIPRANKS
·
Apr 25

Health In Tech to present at Market Movers Investor Summit

Reuters
·
Apr 22